{"id":"W4247747570","doi":"10.2165/00128413-200514910-00054","title":"Omalizumab [Xolair; Novartis] has been launched in Canada for the treatment of moderate-to-severe, persistent asthma","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Omalizumab; Medicine; Asthma; Mepolizumab; Launched; Pharmacy; Family medicine; Internal medicine; Immunology; Immunoglobulin E","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007006494,0.0001972439,0.0003545503,0.0000802984,0.0001036514,0.00001444972,0.0001177044,0.00004223116,0.0002322931],"category_scores_gemma":[0.00002589041,0.0001291986,0.0001933022,0.0001655066,0.00005190451,0.00005106447,0.00001836055,0.00006349709,0.00001755035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007910185,"about_ca_system_score_gemma":0.001478666,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.1305283,"about_ca_topic_score_gemma":0.3123615,"domain_scores_codex":[0.9987299,0.00003401065,0.0003583097,0.000254582,0.0002872844,0.0003358857],"domain_scores_gemma":[0.9991851,0.00011195,0.00007501114,0.0002829482,0.0001117198,0.000233243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01662091,0.005929368,0.0589093,0.000504229,0.001590938,0.0005954867,0.009157894,0.04940791,0.01090535,0.0001229952,0.08793386,0.7583218],"study_design_scores_gemma":[0.01859991,0.003291761,0.1283172,0.0001577785,0.0004570971,0.00008584288,0.003849639,0.02876205,0.01903869,0.000009341111,0.7969009,0.0005297904],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876813,0.002147408,0.00008709994,0.008250366,0.0001388564,0.0011702,0.0001465394,0.00001872981,0.0003595025],"genre_scores_gemma":[0.9967626,0.00004149608,0.0002389475,0.001653649,0.0002531026,0.00009630246,0.0000202193,0.0000271291,0.0009065788],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.757792,"threshold_uncertainty_score":0.8752616,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03356341046701216,"score_gpt":0.2764187798871618,"score_spread":0.2428553694201497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}